{"product_id":"understanding-differentiated-thyroid-carcinoma-a-comprehensive-guide-to-modern-diagnosis-staging-and-treatment","title":"Understanding Differentiated Thyroid Carcinoma: A Comprehensive Guide to Modern Diagnosis, Staging, and Treatment","description":"\u003cp\u003eDifferentiated thyroid carcinoma (DTC) is the most common endocrine cancer, and its rising incidence over recent decades is largely driven by increased diagnostic scrutiny rather than a true increase in dangerous disease — mortality rates have remained unchanged. This updated review from researchers at Radboud University Nijmegen Medical Center in the Netherlands describes a major shift toward more individualized, risk-based management, emphasizing that many low-risk tumors may not need aggressive treatment. Key advances include refined ultrasound-based risk classification systems, molecular testing and FDG-PET imaging to reduce unnecessary surgeries, the introduction of NIFTP (a non-cancer diagnosis for certain encapsulated tumors), active surveillance and minimally invasive techniques for very low-risk papillary microcarcinomas, and clearer evidence about when radioactive iodine therapy is truly beneficial. For patients with advanced or RAI-refractory disease, newer local and systemic treatments are improving progression-free survival, though long-term cure remains challenging.\u003c\/p\u003e\n\n\u003ch1\u003eUnderstanding Differentiated Thyroid Carcinoma: A Comprehensive Guide to Modern Diagnosis, Staging, and Treatment\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eBackground: Why This Research Matters\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#what-is-dtc\"\u003eWhat Is Differentiated Thyroid Carcinoma?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#diagnosis\"\u003eHow DTC Is Diagnosed: Modern Approaches\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#niftp\"\u003eThe NIFTP Reclassification: Removing \"Cancer\" From Select Diagnoses\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#staging\"\u003eInitial and Ongoing Staging: Predicting Risk and Tailoring Care\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#treatment\"\u003eTreatment Strategies: From Surgery to Radioactive Iodine\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#less-surgery\"\u003eA Less Extensive Surgical Approach for Low-Risk DTC\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#rai\"\u003eRadioactive Iodine (RAI) Treatment: New Evidence and Changing Indications\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#advanced\"\u003eTreatment of Locally Advanced, Metastatic, and RAI-Refractory DTC\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#clinical-implications\"\u003eClinical Implications: What These Findings Mean for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations of the Current Evidence\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eMany small, low-risk thyroid cancers may not need aggressive treatment; active surveillance or lobectomy are alternatives.\u003c\/li\u003e\n\u003cli\u003eNIFTP reclassifies 10–20% of previously diagnosed thyroid cancers as non-cancerous, reducing unnecessary treatment.\u003c\/li\u003e\n\u003cli\u003eLow-dose radioactive iodine (1.1 GBq) is as effective as high-dose (3.7 GBq) for low-risk patients in trials.\u003c\/li\u003e\n\u003cli\u003eMolecular testing or FDG-PET can help avoid unnecessary diagnostic surgery for indeterminate thyroid nodules.\u003c\/li\u003e\n\u003cli\u003eFor RAI-refractory advanced disease, new local treatments like thermal ablation can reduce tumor volume and relieve symptoms.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eBackground: Why This Research Matters\u003c\/h2\u003e\n\n\u003cp\u003eThe last few decades have brought a paradox in thyroid cancer care: more people are being diagnosed with thyroid cancer than ever before, yet the number of people dying from it has not changed. This discrepancy has prompted doctors worldwide to rethink how thyroid cancer should be diagnosed and treated.\u003c\/p\u003e\n\n\u003cp\u003eThe explanation for this paradox lies largely in how the disease is detected. With the widespread use of neck ultrasonography (US) and fine needle aspiration (FNA) — procedures that look inside the thyroid gland — doctors are now finding numerous small, clinically indolent (slow-growing, harmless) tumors that would likely never have caused symptoms or harm. In fact, the increased incidence is almost entirely due to more cases of papillary thyroid carcinoma (PTC), the most common type, and has not been associated with any increase in DTC-related mortality.\u003c\/p\u003e\n\n\u003cp\u003eThis awareness has led to a critical reappraisal of DTC management. The focus has shifted away from treating every tumor aggressively and toward achieving two goals at once: reducing unnecessary burden for patients with very low-risk disease, while correctly identifying those who genuinely need more intensive treatment and follow-up. Recent international guidelines from the American Thyroid Association (ATA) and the European Society of Medical Oncology (ESMO) reflect this more individualized, risk-based approach.\u003c\/p\u003e\n\n\u003ch2 id=\"what-is-dtc\"\u003eWhat Is Differentiated Thyroid Carcinoma?\u003c\/h2\u003e\n\n\u003cp\u003eDifferentiated thyroid carcinomas arise from the thyroid follicular cells — the cells in your thyroid gland that produce thyroid hormone. They are the most prevalent malignant (cancerous) tumors of the endocrine system, which is the network of hormone-producing glands in the body.\u003c\/p\u003e\n\n\u003cp\u003eThe three most common variants of DTC are:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePapillary thyroid carcinoma (PTC)\u003c\/strong\u003e — the most common form\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003eFollicular thyroid carcinoma (FTC)\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHürthle cell carcinoma (HTC)\u003c\/strong\u003e — a less common variant\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eTogether, these three types represent \u003cstrong\u003emore than 90% of all thyroid cancers\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eSeveral risk factors are strongly associated with developing DTC:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eA history of DTC in a first-degree relative (parent, sibling, or child)\u003c\/li\u003e\n  \u003cli\u003eExposure to radiation during childhood\u003c\/li\u003e\n  \u003cli\u003eRare genetic syndromes that predispose to cancer\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe incidence of DTC has increased worldwide over the last decades, with a striking gender difference: the incidence in women is \u003cstrong\u003e2.5 to 3 times higher\u003c\/strong\u003e than in men. This increased incidence has been attributed mostly to more widespread use of diagnostic tools like neck ultrasound and FNA, leading to detection of many clinically indolent cases that might otherwise have gone unnoticed.\u003c\/p\u003e\n\n\u003cp\u003eEncouragingly, increased awareness about potential over-diagnosis has led to a stabilization of DTC incidence in the most recent years. Experts believe this is the result of changes in clinical practice, including less frequent use of ultrasound and more restrictive practices concerning FNA, as recommended by the most recent international guidelines.\u003c\/p\u003e\n\n\u003ch2 id=\"diagnosis\"\u003eHow DTC Is Diagnosed: Modern Approaches\u003c\/h2\u003e\n\n\u003cp\u003eDiagnosis and staging of DTC is carried out using a combination of radiologic (imaging-based) and pathologic (tissue-based) methods. The standard diagnostic steps typically follow a structured pathway when a patient presents with a thyroid nodule (a lump in the thyroid gland).\u003c\/p\u003e\n\n\u003ch3\u003eThe Role of Fine Needle Aspiration (FNA)\u003c\/h3\u003e\n\n\u003cp\u003eFNA with cytological examination — using a thin needle to withdraw cells from a nodule for microscopic analysis — remains the single most important diagnostic tool to detect or exclude DTC in patients presenting with thyroid nodules. During FNA, a doctor uses a very thin needle to collect a small sample of cells from the thyroid nodule, which are then examined under a microscope.\u003c\/p\u003e\n\n\u003cp\u003eSelection of patients who undergo FNA should be based on clinical features and ultrasound nodule characteristics. Most recent international guidelines recommend restricting FNA to patients with nodules larger than 1 centimeter (about 0.4 inches), unless there is high clinical or ultrasound suspicion of malignancy. This includes thyroid nodules showing focal (localized) uptake on FDG-PET scans (a specialized imaging test that shows areas of high metabolic activity), which have been shown to be associated with a higher risk of malignancy.\u003c\/p\u003e\n\n\u003cp\u003eGiven that most papillary thyroid microcarcinomas (PTMC — tumors smaller than 1 cm) that are limited to the thyroid carry a very low risk of becoming clinically overt (causing symptoms), the decision to perform FNA in nodules under 1 cm should strongly consider the patient's overall clinical context and carefully balance the potential risks and benefits of subsequent procedures. For these tiny tumors, \u003cstrong\u003eactive surveillance\u003c\/strong\u003e (monitoring the tumor over time rather than treating it immediately) is the recommended option.\u003c\/p\u003e\n\n\u003ch3\u003eUltrasound Risk Classification: The TIRADS Systems\u003c\/h3\u003e\n\n\u003cp\u003eDiagnostic neck ultrasound should be performed in all patients with a suspicion of a thyroid nodule. It is required to describe the characteristics of the thyroid nodule(s) and to assess the cervical (neck) lymph nodes for signs of cancer spread.\u003c\/p\u003e\n\n\u003cp\u003eTo categorize thyroid nodules by malignancy risk and to adequately select patients who require FNA, Kwak and colleagues developed the \u003cstrong\u003eThyroid Imaging Reporting and Data System (TIRADS)\u003c\/strong\u003e criteria in 2011, based on the sonographic (ultrasound) features of thyroid nodules. This system is endorsed by the American College of Radiology (ACR). Other medical societies — including the ATA, the European Thyroid Association (ETA), and the Korean Society of Thyroid Radiology (KSThR) — have proposed different criteria for the same purpose, resulting in EU-TIRADS and K-TIRADS classifications.\u003c\/p\u003e\n\n\u003cp\u003eRecently, a meta-analysis (a study that combines the results of multiple studies) of comparative studies on these different criteria concluded that, when compared head-to-head, the \u003cstrong\u003eACR-TIRADS had a significantly higher diagnostic odds ratio\u003c\/strong\u003e — meaning better overall diagnostic performance — than the ATA or K-TIRADS criteria. An accurate comparison with EU-TIRADS could not be performed because only a small number of studies using EU-TIRADS were included. The meta-analysis mostly included retrospective cohort studies, and more prospective studies are needed to conclude which criteria are truly superior in selecting thyroid nodules that require FNA.\u003c\/p\u003e\n\n\u003cp\u003eHere is what the different ultrasound classification systems look like in practical terms:\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eACR-TIRADS\u003c\/strong\u003e assigns points based on composition, echogenicity (how the nodule appears on ultrasound), shape, margin, and echogenic foci (tiny bright spots):\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e0 points: malignancy risk less than 2% — no FNA recommended\u003c\/li\u003e\n  \u003cli\u003e2 points: malignancy risk less than 2% — no FNA recommended\u003c\/li\u003e\n  \u003cli\u003e3 points: malignancy risk 5% — FNA recommended for nodules 2.5 cm or larger\u003c\/li\u003e\n  \u003cli\u003e4–6 points: malignancy risk 5–20% — FNA recommended for nodules 1.5 cm or larger\u003c\/li\u003e\n  \u003cli\u003e7 or more points: malignancy risk greater than 20% — FNA recommended for nodules 1 cm or larger\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eEU-TIRADS\u003c\/strong\u003e categories include:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eNo nodule: risk 0%\u003c\/li\u003e\n  \u003cli\u003ePure cyst or entirely spongiform (honeycomb appearance): risk 0% — no FNA unless compressive symptoms\u003c\/li\u003e\n  \u003cli\u003eOval, smooth, isoechoic\/hyperechoic (similar or brighter appearance than surrounding tissue): risk 2–4% — FNA for nodules over 2 cm\u003c\/li\u003e\n  \u003cli\u003eOval, smooth, mildly hypoechoic (darker appearance): risk 6–17% — FNA for nodules over 1.5 cm\u003c\/li\u003e\n  \u003cli\u003eAt least one feature of high suspicion (irregular shape, irregular margins, microcalcifications, marked hypo-echogenicity): risk 26–87% — FNA for nodules over 1 cm\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eK-TIRADS\u003c\/strong\u003e categories include:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eNo nodule: risk 0%\u003c\/li\u003e\n  \u003cli\u003eSpongiform or partially cystic nodule with comet-tail artifact or pure cyst: risk less than 3% — no FNA\u003c\/li\u003e\n  \u003cli\u003ePartially cystic or isohyperechoic nodule without any of 3 suspicious features (microcalcification, nonparallel orientation, spiculated or microlobulated margin): risk 3–15% — FNA for nodules 1.5 cm or larger\u003c\/li\u003e\n  \u003cli\u003eSolid hypoechoic nodule without suspicious features, or partially cystic\/isoechoic nodule with any suspicious feature: risk 15–50% — FNA for nodules 1 cm or larger\u003c\/li\u003e\n  \u003cli\u003eSolid hypoechoic nodule with any of the 3 suspicious features: risk greater than 60% — FNA for nodules 1 cm or larger\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eATA classification\u003c\/strong\u003e (categories are named rather than numbered):\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eBenign: risk less than 1% — no FNA\u003c\/li\u003e\n  \u003cli\u003eVery low suspicion (spongiform or partially cystic without any sonographic features described in low, intermediate, or high suspicion): risk less than 3% — consider FNA at 2 cm or larger\u003c\/li\u003e\n  \u003cli\u003eLow suspicion (isoechoic or hyperechoic solid or partially cystic nodule without microcalcification, irregular margin, or extrathyroidal extension, or taller-than-wide shape): risk 5–10% — recommend FNA at 1.5 cm or larger\u003c\/li\u003e\n  \u003cli\u003eIntermediate suspicion (hypoechoic solid nodule with smooth margins without microcalcifications, extrathyroidal extension, or taller-than-wide shape): risk 10–20% — recommend FNA at 1.5 cm or larger\u003c\/li\u003e\n  \u003cli\u003eHigh suspicion (solid hypoechoic nodule or solid hypoechoic component of a partially cystic nodule with irregular margins, microcalcifications, taller-than-wide shape, rim calcifications with small extrusive soft tissue component, and\/or extrathyroidal extension): risk greater than 70–90% — recommend FNA at 1 cm or larger\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eUnderstanding FNA Results: The Bethesda System\u003c\/h3\u003e\n\n\u003cp\u003eThe FNA result is expressed as one of six Bethesda categories, a standardized reporting system that helps doctors communicate cytology findings consistently. While Bethesda categories 2 and 6 can accurately identify benign and malignant nodules respectively, categories 3, 4, and 5 have large interobserver variability — meaning different pathologists may interpret the same sample differently — and cannot reliably distinguish between malignant and benign nodules.\u003c\/p\u003e\n\n\u003cp\u003eThis uncertainty is significant because many patients with nodules in these indeterminate categories undergo diagnostic lobectomy (surgical removal of one thyroid lobe) to rule out malignancy. Particularly for those with Bethesda 3 and 4 categories, which carry an \u003cstrong\u003eestimated risk of malignancy up to 30%\u003c\/strong\u003e, many of these surgeries could be unnecessary.\u003c\/p\u003e\n\n\u003ch3\u003eMolecular Testing and FDG-PET: Reducing Unnecessary Surgeries\u003c\/h3\u003e\n\n\u003cp\u003eTo reduce the number of diagnostic surgeries for nodules in the indeterminate Bethesda categories, several diagnostic advancements have been proposed:\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eMolecular testing\u003c\/strong\u003e — Tests based on DNA or RNA technologies, either limited to diagnostic mutational panels (which look for specific known cancer-causing gene mutations) or a gene expression classifier (which analyzes the activity of many genes to predict whether a nodule is benign or malignant). These tests have been developed to refine diagnostic accuracy in the Bethesda 3 and 4 categories, with reported sensitivity (correctly identifying cancer when present) of about 90% for most tests, and specificity (correctly identifying benign when benign) between 49% and 92%. While the reported negative predictive value — the probability that a patient truly does not have cancer when the test is negative — is about 95% for most of them, making them suitable as rule-out tests, the positive predictive value — the probability that a patient truly has cancer when the test is positive — varies widely between 37% and 82%.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFDG-PET imaging\u003c\/strong\u003e — A systematic review and meta-analysis by Vriens and colleagues indicates that the lack of FDG-PET uptake in nodules larger than 15 mm with indeterminate cytology excludes malignancy with a \u003cstrong\u003e100% sensitivity\u003c\/strong\u003e in those nodules. Furthermore, a recent randomized controlled trial indicates that an FDG-PET\/CT-based diagnostic approach toward indeterminate nodules can reduce up to \u003cstrong\u003e40% of unnecessary diagnostic surgeries\u003c\/strong\u003e, provided that the nodules are not Hürthle cell neoplasia, which often show increased FDG-PET uptake even when benign.\u003c\/p\u003e\n\n\u003cp\u003eUsed in conjunction with clinical evaluation and other available tools, these techniques have the potential to improve the preoperative diagnostic accuracy of thyroid nodules. Future studies are warranted to establish the most clinically and cost-effective approach algorithm to optimize the diagnostic pathway.\u003c\/p\u003e\n\n\u003ch2 id=\"niftp\"\u003eThe NIFTP Reclassification: Removing \"Cancer\" From Select Diagnoses\u003c\/h2\u003e\n\n\u003cp\u003eIn another effort to reduce the burden of DTC diagnosis and treatment, Nikiforov and colleagues introduced the term \u003cstrong\u003enon-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP)\u003c\/strong\u003e to replace the encapsulated follicular variant of papillary thyroid carcinoma (EFVPTC), estimated to represent \u003cstrong\u003e10–20% of all DTC diagnosed in Europe and North America\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eThe motivation behind this reclassification is profound: by removing the word \"cancer\" from this diagnosis, the goal was to promote a more conservative treatment strategy for NIFTP, with a lesser burden to the patient. This reflects a growing recognition that not all abnormal growths labeled as cancer behave like cancer.\u003c\/p\u003e\n\n\u003cp\u003eNIFTPs show a rather indolent (slow-growing, harmless) behavior. Several studies on clinical outcomes of patients with NIFTP have shown \u003cstrong\u003etotal absence of lymph node or distant metastases during follow-up\u003c\/strong\u003e. Other studies showed low rates of microscopic (smaller than 2 mm) lymph node metastases, ranging from 2% to 5%. However, some of these tumors showed features characteristic of classic PTC, and not all tumors were entirely sampled (examined). Therefore, the diagnostic criteria of NIFTP were updated in 2018 and now exclude tumors with well-formed papillae (finger-like projections).\u003c\/p\u003e\n\n\u003cp\u003eAdditionally, the absence of mutations typical for PTC — specifically \u003cstrong\u003eBRAFV600E, TERT, and TP53\u003c\/strong\u003e mutations — was added as a secondary criterion, and examination of the entire tumor became mandatory. Genetic events that are more commonly detected in FTC, such as RAS mutations or PAX8\/PPARg rearrangements, cannot distinguish between follicular carcinoma and adenoma (including Hürthle cell variants) and have not been included in the diagnostic criteria.\u003c\/p\u003e\n\n\u003cp\u003eFor patients, this reclassification means that some individuals who would previously have been told they had thyroid cancer and received aggressive treatment are now diagnosed with a non-cancer condition that can be managed more conservatively, with less surgery, less radioactive iodine, and less psychological burden.\u003c\/p\u003e\n\n\u003ch2 id=\"staging\"\u003eInitial and Ongoing Staging: Predicting Risk and Tailoring Care\u003c\/h2\u003e\n\n\u003cp\u003eIn DTC, different staging systems serve different purposes:\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eThe tumor, node, metastasis (TNM) classification system\u003c\/strong\u003e is optimized to predict mortality (death) from DTC. It classifies the tumor based on its size and extent (T), whether it has spread to lymph nodes (N), and whether it has spread to distant organs (M).\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eThe risk stratification proposed by the ATA and ESMO guidelines\u003c\/strong\u003e predicts recurrence (the cancer coming back), which is a more relevant outcome measure in DTC because most patients survive their disease and the main concern is recurrence.\u003c\/p\u003e\n\n\u003cp\u003eThese staging systems can be used as guidance for initial treatment strategies. But importantly, risk stratification should not stop at the time of diagnosis — it should continue during follow-up.\u003c\/p\u003e\n\n\u003cp\u003eThis ongoing stratification system was first described by Tuttle and colleagues and later modified by Vaisman and colleagues. It is based on response to therapy, on which patients should be stratified during their follow-up into four categories:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eExcellent response\u003c\/strong\u003e — no evidence of disease anywhere\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBiochemical incomplete response\u003c\/strong\u003e — abnormal blood markers (like thyroglobulin levels) but no visible disease on imaging\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eStructural incomplete response\u003c\/strong\u003e — visible evidence that the disease has returned or persisted\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIndeterminate response\u003c\/strong\u003e — findings that are not clearly normal or clearly abnormal\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eThis stratification system can predict both recurrence and mortality, has been validated by several studies, and can guide the intensity of follow-up — meaning follow-up can be relaxed for those responding excellently and intensified for those with incomplete responses.\u003c\/p\u003e\n\n\u003cp\u003eOn the molecular front, tumors bearing pathologic BRAF mutations — particularly in combination with TERT mutations — have been associated with unfavorable outcomes. However, although molecular testing is expected to contribute in the future to prognostic assessment, at the moment the way it can be practically used for this purpose has not yet been robustly established.\u003c\/p\u003e\n\n\u003ch2 id=\"treatment\"\u003eTreatment Strategies: From Surgery to Radioactive Iodine\u003c\/h2\u003e\n\n\u003cp\u003eThe treatment strategy for DTC patients mostly consists of a combination of three approaches:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSurgery\u003c\/strong\u003e — removing part or all of the thyroid gland\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRadioactive iodine (RAI) administration\u003c\/strong\u003e — using radioactive iodine to destroy remaining thyroid tissue or cancer cells\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eThyrotropin (TSH) suppression therapy\u003c\/strong\u003e — using thyroid hormone medication to keep TSH levels low, which can slow the growth of any remaining thyroid cancer cells\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eThe extent of the different treatment modalities depends on initial and ongoing risk stratification. Recent developments have questioned some traditional treatment strategies, particularly with respect to low-risk DTC, while other treatment modalities have been introduced.\u003c\/p\u003e\n\n\u003ch2 id=\"less-surgery\"\u003eA Less Extensive Surgical Approach for Low-Risk DTC\u003c\/h2\u003e\n\n\u003cp\u003eTotal thyroidectomy (removal of the entire thyroid gland) has been the standard surgical procedure for the management of DTC. For patients with intermediate- and high-risk DTC, total thyroidectomy with the addition of neck lymph node dissection — in cases where there is clinical or ultrasound evidence of lymph node metastases — remains the recommended initial surgical approach.\u003c\/p\u003e\n\n\u003cp\u003eHowever, several large retrospective studies have shown that in low-risk papillary thyroid microcarcinoma (PTMC) and in carefully selected low-risk DTC patients, \u003cstrong\u003eunilateral lobectomy\u003c\/strong\u003e (removing only the thyroid lobe containing the tumor) can be an alternative without reducing survival rates or increasing the risk of recurrence. Because unilateral lobectomy is associated with lower complication rates and lower costs, large multicenter prospective randomized controlled trials to validate these findings would be very valuable. Nonetheless, given the high long-term survival and low prevalence of recurrences associated with these tumors, a well-powered prospective randomized study requires very large patient groups and lengthy follow-up — which are likely only feasible based on non-inferiority endpoints (proving the less extensive treatment is not worse than the standard one).\u003c\/p\u003e\n\n\u003cp\u003eMoreover, uniform protocols need to be established for the intensity and duration of follow-up in patients with low-risk DTC who undergo lobectomy as primary treatment.\u003c\/p\u003e\n\n\u003cp\u003eFor patients with low-risk PTMC, defined as unifocal (single) tumors limited to the thyroid, without extrathyroidal extension (spread beyond the thyroid), without clinical or ultrasound evidence of lymph node or distant metastases, and without other risk factors such as worrisome pathological features (e.g., tall cell, insular, or columnar cell variants) or molecular features (e.g., combination of pathological BRAF and TERT mutations), \u003cstrong\u003eunilateral lobectomy is the recommended treatment\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eMinimally Invasive Techniques (MIT) and Active Surveillance\u003c\/h3\u003e\n\n\u003cp\u003eMoving even further away from aggressive surgery, several studies summarized in recent systematic reviews and meta-analyses indicate that patients with low-risk PTMC are eligible for image-guided minimally invasive techniques (MIT), particularly thermal ablation — using heat to destroy the tumor. The main thermal ablation methods include:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\u003cstrong\u003eLaser ablation (LA)\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003eRadiofrequency ablation (RFA)\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003eMicrowave ablation (MWA)\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThese techniques achieve comparable results to surgery with respect to local disease control and have low complication rates. Therefore, in centers where expertise is available, MIT can be offered as an alternative to surgery in patients with incidentally discovered low-risk PTMC who are not eligible for surgery or who decline it.\u003c\/p\u003e\n\n\u003cp\u003eThe European Thyroid Association (ETA) and the Cardiovascular and Interventional Radiological Society of Europe have recently published a guideline on application of MIT in thyroid carcinoma. This document describes the techniques that are suitable for different indications and details the characteristics of patients who could be eligible for MIT.\u003c\/p\u003e\n\n\u003cp\u003eFurthermore, accumulating evidence indicates that \u003cstrong\u003eactive surveillance\u003c\/strong\u003e (carefully monitoring the tumor without immediate treatment) can provide a safe option in selected patients with low-risk PTMC who are not eligible for surgery or who decline it.\u003c\/p\u003e\n\n\u003cp\u003eCurrently, no studies are available providing head-to-head comparison of these treatment modalities (surgery, MIT, and active surveillance) for PTMC, and there is still limited long-term data available on the outcome of patients treated by MIT or undergoing active surveillance, particularly in populations of European descent. Nonetheless, as these approaches are being increasingly used in Europe and the USA, it is expected that more studies will accumulate knowledge on the safety and long-term outcome of these procedures and their potential to improve long-term quality of life for patients with DTC.\u003c\/p\u003e\n\n\u003cp\u003eImportantly, broader implementation of \u003cstrong\u003eshared decision-making\u003c\/strong\u003e should enable better participation of patients in decisions about their management. Shared decision-making can help improve communication with physicians, provide better empowerment and satisfaction — leading to decisions that better match patients' preferences and expectations.\u003c\/p\u003e\n\n\u003ch2 id=\"rai\"\u003eRadioactive Iodine (RAI) Treatment: New Evidence and Changing Indications\u003c\/h2\u003e\n\n\u003cp\u003eGiven the evidence of improved prognosis of patients with DTC after the introduction of RAI treatment following surgery, RAI treatment has been recommended for many years for the large majority of DTC patients. In the past decade, however, the place of RAI in the treatment armamentarium for DTC was reappraised, considering the more individualized, risk assessment-based approach.\u003c\/p\u003e\n\n\u003cp\u003eIn patients with DTC, RAI can be administered for several indications:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRemnant ablation\u003c\/strong\u003e — destroying normal thyroid tissue remnant after surgery, which renders follow-up of thyroglobulin levels (a blood marker for thyroid tissue or cancer) sensitive for DTC recurrence\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAdjuvant setting\u003c\/strong\u003e — destroying presumed microscopic foci of DTC, thus reducing recurrence risk\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003eTreatment of persistent or recurrent disease\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe additive value of post-surgical RAI treatment should be based on individual prognostic factors regarding risk of cancer-related death or disease recurrence. For this, the aforementioned risk stratification is paramount. While it is widely agreed that post-surgical RAI treatment is indicated in high-risk DTC patients, there is less consensus regarding the indications in intermediate- and low-risk patients.\u003c\/p\u003e\n\n\u003ch3\u003eIntermediate-Risk Patients\u003c\/h3\u003e\n\n\u003cp\u003eIn intermediate-risk patients, individual risk factors should be considered when estimating the benefits of RAI treatment. A systematic review by Sacks and colleagues concluded that survival was improved in DTC patients older than 45 years with TNM stage III who received RAI treatment compared to patients who did not. The benefit in patients younger than 45 years was unclear.\u003c\/p\u003e\n\n\u003cp\u003eThe recent ETA consensus statement indicates that the following factors have been associated with the greatest benefit of adjuvant RAI treatment:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eAdvanced age\u003c\/li\u003e\n  \u003cli\u003eAggressive histology (tumor appearance under the microscope)\u003c\/li\u003e\n  \u003cli\u003eLarge volume of nodal disease\u003c\/li\u003e\n  \u003cli\u003eExtranodal extension (spread of cancer beyond the lymph node capsule)\u003c\/li\u003e\n  \u003cli\u003eMultiple N1 (lymph node positive) and\/or lymph node metastases outside the central neck\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eMore prospective studies are needed to further elucidate the individual factors associated with benefit from RAI treatment in intermediate-risk DTC patients.\u003c\/p\u003e\n\n\u003ch3\u003eLow-Risk Patients: Landmark Trial Results\u003c\/h3\u003e\n\n\u003cp\u003eThe benefit of post-surgical RAI treatment in low-risk patients is, in light of emerging evidence, highly debated. As shown by a systematic review by Verbrug and colleagues including 11 retrospective cohort studies, results are not consistent.\u003c\/p\u003e\n\n\u003cp\u003eRecently, a landmark randomized controlled trial by Leboulleux and colleagues showed that in patients with low-risk DTC undergoing thyroidectomy, a follow-up strategy \u003cstrong\u003ewithout RAI remnant ablation was non-inferior\u003c\/strong\u003e (not worse) to a follow-up strategy including RAI remnant ablation. The primary endpoint was the percentage of patients without an event during 3 years after randomization. This event was a composite endpoint of functional, structural, and biologic criteria. More studies are needed to validate these findings, particularly to assess long-term outcomes. Until then, the indication for RAI treatment in low-risk DTC patients should be based on individual prognostic risk factors.\u003c\/p\u003e\n\n\u003cp\u003eRegarding the RAI activity (dose) required in low-risk DTC patients, two large randomized controlled trials have compared high-dose post-operative RAI ablation (3.7 GBq) with low-dose (1.1 GBq):\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eThe ESTIMABL1 trial\u003c\/strong\u003e was conducted in 24 centers in France between 2007 and 2010. It included \u003cstrong\u003e752 low-risk DTC patients\u003c\/strong\u003e, randomized between four treatment strategies: low or high dose RAI ablation combined with TSH stimulation using either recombinant human TSH (rhTSH — a synthetic form of TSH given by injection) or thyroid hormone withdrawal (stopping thyroid hormone medication to raise natural TSH levels). After a median follow-up of \u003cstrong\u003e5.4 years\u003c\/strong\u003e, no differences in recurrence rates were found between the different treatment strategies.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eThe HiLo trial\u003c\/strong\u003e took place in 29 centers in the United Kingdom, also between 2007 and 2010. In this study, \u003cstrong\u003e438 patients\u003c\/strong\u003e were randomized between the same treatment strategies as the ESTIMABL1 trial. The results showed no significant differences in recurrence rates between the treatment strategies after a median follow-up of \u003cstrong\u003e6.5 years\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eBased on this data, it is currently recommended that, if post-surgical remnant ablation is prescribed in low-risk patients, this can take place using \u003cstrong\u003e1.1 GBq of 131I (low-dose) preceded by rhTSH\u003c\/strong\u003e. This approach reduces the amount of radioactivity administered and the discomfort caused by thyroid hormone withdrawal — which can cause symptoms of hypothyroidism (fatigue, weight gain, depression) for several weeks.\u003c\/p\u003e\n\n\u003ch2 id=\"advanced\"\u003eTreatment of Locally Advanced, Metastatic, and RAI-Refractory DTC\u003c\/h2\u003e\n\n\u003cp\u003eMost DTC patients have an excellent prognosis, with a \u003cstrong\u003e10-year survival around 90%\u003c\/strong\u003e. Nonetheless, a minority develops recurrent or metastatic (spread to distant organs) disease, and of these, approximately \u003cstrong\u003e40% become resistant to conventional treatment\u003c\/strong\u003e — meaning their tumors no longer take up radioactive iodine.\u003c\/p\u003e\n\n\u003cp\u003eThe overall survival for patients with advanced or metastatic DTC resistant to RAI therapy is poor, with \u003cstrong\u003e5-year survival rates of 50% and 10-year survival rates of 10%\u003c\/strong\u003e. Treatment options for these patients are limited and rarely result in cure of the disease. Nevertheless, during the last decades, new treatment modalities have been introduced that have improved \u003cstrong\u003eprogression-free survival (PFS)\u003c\/strong\u003e — the length of time during and after treatment that a patient lives with the disease without it getting worse. These include both local and systemic treatments.\u003c\/p\u003e\n\n\u003ch3\u003eLocal Treatment Options\u003c\/h3\u003e\n\n\u003cp\u003eIn case of recurrent disease, surgical removal of metastases and\/or RAI treatment (as long as the tumor has not become refractory) are the preferred treatment modalities. For patients with RAI-refractory DTC that are not amenable to surgery — such as patients in poor condition, patients declining surgery, or patients with unresectable (cannot be surgically removed) disease — other local treatment options are available, such as external beam radiotherapy (radiation delivered from outside the body) and, more recently introduced, image-guided minimally invasive techniques (MIT).\u003c\/p\u003e\n\n\u003cp\u003eIn unresectable DTC, MIT may be used for symptomatic tumor volume reduction. Two case series of unresectable local recurrent DTC treated with radiofrequency ablation (RFA) showed \u003cstrong\u003evolume reduction rates of 51% and 81%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eMIT can also be used for reduction of symptoms caused by distant metastases. DTC most commonly metastasizes to the lungs and bones. A recent retrospective multicenter study investigated the efficacy and safety of MIT (RFA, microwave ablation, and cryoablation — freezing the tumor) in pulmonary (lung) DTC metastases. After a median follow-up of \u003cstrong\u003e5.2 years\u003c\/strong\u003e, local tumor progression was observed in \u003cstrong\u003e4 of 34 DTC patients\u003c\/strong\u003e, and no major complications occurred.\u003c\/p\u003e\n\n\u003cp\u003eTwo prospective multicenter trials studied the efficacy of RFA and cryoablation in \u003cstrong\u003e55 and 61 patients\u003c\/strong\u003e, respectively, with symptomatic bone metastases — including DTC patients as part of a broader group. These studies help establish MIT as a viable option for reducing pain and local symptoms from bone metastases.\u003c\/p\u003e\n\n\u003ch2 id=\"clinical-implications\"\u003eClinical Implications: What These Findings Mean for Patients\u003c\/h2\u003e\n\n\u003cp\u003eThis review represents a fundamental shift in how thyroid cancer is perceived and managed, with several direct implications for patients:\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFirst, not every thyroid cancer needs aggressive treatment.\u003c\/strong\u003e Many small, low-risk tumors can be safely managed with active surveillance, lobectomy rather than total thyroidectomy, or minimally invasive thermal ablation — all of which carry fewer side effects and less impact on quality of life than traditional approaches.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eSecond, the diagnosis itself is being refined.\u003c\/strong\u003e With the introduction of NIFTP — which affects 10–20% of what was previously diagnosed as thyroid cancer in Europe and North America — some patients are now spared the diagnosis of cancer entirely, along with the psychological burden and aggressive treatment that comes with it.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eThird, RAI treatment is no longer automatic.\u003c\/strong\u003e The evidence from the ESTIMABL1 and HiLo trials shows that for low-risk patients, low-dose RAI (1.1 GBq) is as effective as high-dose (3.7 GBq), and — following the Leboulleux trial — some low-risk patients may not need RAI at all. This means less radiation exposure, fewer side effects, and less disruption to daily life from thyroid hormone withdrawal.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFourth, advanced disease is no longer hopeless.\u003c\/strong\u003e Although RAI-refractory DTC has historically had poor outcomes — with 5-year survival of 50% and 10-year survival of 10% — newer local treatments like thermal ablation for lung and bone metastases, along with systemic therapies, are improving progression-free survival. For patients with unresectable local recurrences, RFA has shown tumor volume reduction rates of 51–81%, offering meaningful symptom relief.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFifth, shared decision-making is essential.\u003c\/strong\u003e Given the growing number of valid treatment options — surgery, MIT, active surveillance — with comparable outcomes for low-risk disease, patients should be active participants in choosing their care path. The authors emphasize that shared decision-making improves communication, patient empowerment, and satisfaction.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eLimitations of the Current Evidence\u003c\/h2\u003e\n\n\u003cp\u003eWhile this review presents robust evidence for the changing landscape of DTC management, several limitations should be acknowledged:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eThe meta-analysis comparing TIRADS classification systems mostly included retrospective cohort studies, which are more prone to bias than prospective studies. Only a small number of studies using EU-TIRADS were available, preventing an accurate comparison of EU-TIRADS performance.\u003c\/li\u003e\n  \u003cli\u003eMolecular testing in indeterminate thyroid nodules shows variable positive predictive values (37–82%), meaning a positive test does not always confirm cancer, and the most clinically and cost-effective testing algorithm has not yet been established.\u003c\/li\u003e\n  \u003cli\u003eRegarding MIT and active surveillance for low-risk PTMC, no head-to-head comparison studies exist, and long-term outcome data are limited — particularly in European-derived populations.\u003c\/li\u003e\n  \u003cli\u003eFor the recommendation of lobectomy over total thyroidectomy in low-risk disease, the supporting evidence comes largely from large retrospective studies rather than prospective randomized trials. The authors note that well-powered prospective randomized studies are very difficult to conduct because of the high survival rates and long follow-up required.\u003c\/li\u003e\n  \u003cli\u003eThe evidence for omitting RAI in low-risk patients is based primarily on the single randomized trial by Leboulleux and colleagues with 3-year follow-up; longer-term outcomes are still needed.\u003c\/li\u003e\n  \u003cli\u003eIn intermediate-risk patients, the factors associated with RAI benefit have been identified largely from retrospective analyses and expert consensus, with more prospective studies needed.\u003c\/li\u003e\n  \u003cli\u003eWhile molecular markers like BRAF and TERT mutations are known to be associated with unfavorable outcomes, the practical integration of molecular testing into routine prognostic assessment has not yet been robustly established.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations for Patients\u003c\/h2\u003e\n\n\u003cp\u003eBased on this update, patients and their families may find the following points useful when discussing care with their medical team:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about active surveillance for small tumors.\u003c\/strong\u003e If you have a papillary thyroid microcarcinoma (under 1 cm) confined to the thyroid, active surveillance may be a safe option. Ask your doctor about the risks and benefits of monitoring versus immediate treatment.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eExplore all surgical options.\u003c\/strong\u003e If you have low-risk DTC, ask whether unilateral lobectomy (removing only the affected lobe) might be appropriate rather than total thyroidectomy. This can mean a lower risk of complications and potentially no need for lifelong thyroid hormone replacement.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about minimally invasive techniques (MIT).\u003c\/strong\u003e For low-risk microcarcinomas, thermal ablation (laser, radiofrequency, or microwave) may be an option if you are not eligible for surgery or prefer to avoid it. These procedures are performed at specialized centers with appropriate expertise.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIf you have indeterminate results on FNA (Bethesda 3 or 4), ask about additional testing.\u003c\/strong\u003e Molecular testing (with roughly 90% sensitivity) or FDG-PET imaging (for nodules over 15 mm) may help you avoid an unnecessary diagnostic surgery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about RAI dosing.\u003c\/strong\u003e If RAI treatment is recommended for low-risk disease, ask whether the low-dose regimen (1.1 GBq) with rhTSH stimulation is appropriate rather than high-dose RAI with thyroid hormone withdrawal. Ask whether RAI is needed at all based on your individual risk factors.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRequest ongoing risk stratification during follow-up.\u003c\/strong\u003e Your treatment plan should be re-evaluated over time based on your response to therapy (excellent, biochemical incomplete, structural incomplete, or indeterminate). This determines whether follow-up intensity can be reduced or should be increased.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eParticipate in shared decision-making.\u003c\/strong\u003e Ask your medical team to explain the trade-offs between treatment options, including side effects, quality-of-life impacts, and long-term outcomes. The best decision is one that aligns with your values, preferences, and expectations.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFor advanced or RAI-refractory disease, ask about local treatment options.\u003c\/strong\u003e Image-guided minimally invasive techniques can reduce tumor volume and relieve symptoms from unresectable recurrences or lung and bone metastases, with low complication rates based on recent studies.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eI was just told I have a small thyroid cancer under 1 cm. Do I need surgery right away?\u003c\/h3\u003e\n\u003cp\u003eFor a papillary thyroid microcarcinoma confined to the thyroid, active surveillance—careful monitoring without immediate treatment—may be a safe option. This is recommended when there are no worrisome features. Ask your doctor whether monitoring versus immediate surgery is appropriate for your specific situation.\u003c\/p\u003e\n\u003ch3\u003eMy thyroid nodule biopsy came back as indeterminate (Bethesda 3 or 4). Can I avoid surgery?\u003c\/h3\u003e\n\u003cp\u003eYes, additional tests may help. Molecular testing has about 90% sensitivity for detecting cancer, and a negative result means a roughly 95% chance it is benign. FDG-PET scanning for nodules larger than 15 mm can also help—a lack of uptake may rule out cancer. These tests may reduce unnecessary diagnostic surgeries.\u003c\/p\u003e\n\u003ch3\u003eWhat is NIFTP and does it mean I don't have cancer?\u003c\/h3\u003e\n\u003cp\u003eNIFTP stands for non-invasive follicular thyroid neoplasm with papillary-like nuclear features. It was introduced to replace a previously diagnosed form of thyroid cancer. Tumors meeting strict criteria are now considered non-cancerous. This means some patients can avoid aggressive treatment and the psychological burden of a cancer diagnosis.\u003c\/p\u003e\n\u003ch3\u003eI have low-risk thyroid cancer. Can I have just a lobectomy instead of removing the whole thyroid?\u003c\/h3\u003e\n\u003cp\u003eFor carefully selected low-risk patients, unilateral lobectomy—removing only the lobe containing the tumor—can be an alternative to total thyroidectomy. Studies suggest it does not reduce survival or increase recurrence risk for these patients. Lobectomy also has fewer complications and may avoid lifelong thyroid hormone replacement.\u003c\/p\u003e\n\u003ch3\u003eI was told I need radioactive iodine treatment. Is the full dose always necessary?\u003c\/h3\u003e\n\u003cp\u003eNo. For low-risk patients, two large trials found that low-dose radioactive iodine (1.1 GBq) was as effective as high-dose (3.7 GBq) in preventing recurrence. Another study showed that for some low-risk patients, no radioactive iodine at all was not worse than receiving it. Always discuss your individual risk factors.\u003c\/p\u003e\n\u003ch3\u003eWhat does it mean if my thyroid cancer is called RAI-refractory?\u003c\/h3\u003e\n\u003cp\u003eRAI-refractory means the cancer no longer takes up radioactive iodine, so that treatment is no longer helpful. Historically, survival was poor, but newer local and systemic treatments are improving progression-free survival. For example, thermal ablation can shrink unresectable recurrences and metastases, providing symptom relief with low complication rates.\u003c\/p\u003e\n\u003ch3\u003eHow will my doctor know if my treatment is working during follow-up?\u003c\/h3\u003e\n\u003cp\u003eYou will be regularly re-evaluated and placed into one of four response categories: excellent (no evidence of disease), biochemical incomplete (abnormal blood markers but no visible disease), structural incomplete (visible disease), or indeterminate (unclear findings). This ongoing risk stratification guides whether follow-up can be relaxed or needs to be more intensive.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal Article Title:\u003c\/strong\u003e Differentiated thyroid carcinoma- An update\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eJournal:\u003c\/strong\u003e Best Practice \u0026amp; Research Clinical Endocrinology \u0026amp; Metabolism, Volume 37, 2023, Article 101687. Available online 12 August 2022. Published by Elsevier Ltd.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eDOI:\u003c\/strong\u003e https:\/\/doi.org\/10.1016\/j.beem.2022.101687\u003c\/p\u003e\n\n\u003cp\u003eThis patient-friendly article is based on peer-reviewed research. The original article is an open-access publication under the CC BY-NC-ND license (creativecommons.org\/licenses\/by-nc-nd\/4.0\/).\u003c\/p\u003e\n\n\u003cp\u003e\u003cem\u003eNote: This content is intended for educational purposes and should not replace professional medical advice. Always discuss your individual situation with your healthcare provider.\u003c\/em\u003e\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47422999265436,"sku":null,"price":0.0,"currency_code":"EUR","in_stock":true}],"url":"https:\/\/diagnosticdetectives.de\/products\/understanding-differentiated-thyroid-carcinoma-a-comprehensive-guide-to-modern-diagnosis-staging-and-treatment","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}